The Role of Neuroinflammation in Parkinson's Disease

Neuroinflammation

Volumn , Issue , 2011, Pages 403-421

  Chen, Xi ^a   Tansey, Malú G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872872016     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384913-7.00018-6     Document Type: Chapter

References (144)

1. Hirsch EC, Hunot S Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009 1998, 8(4):382-397.
2. Fahn S Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003, 991:1-14.
3. Dawson TM, Dawson VL The role of parkin in familial and sporadic Parkinson's disease. Mov Disord 2010, 25(Suppl. 1):S32-9.
4. Dauer W, Przedborski S Parkinson's disease: mechanisms and models. Neuron 2003, 39(6):889-909.
5. Farrer MJ Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006, 7(4):306-318.
6. Tanner CM Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 2003, 91:133-142.
7. Tansey MG, McCoy MK, Frank-Cannon TC Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention. Exp Neurol 2007, 208(1):1-25.
8. Mizuno Y, Hattori N, Kitada T, Matsumine H, Mori H, Shimura H, et al. Familial Parkinson's disease. Alpha-synuclein and parkin. Adv Neurol 2001, 86:13-21.
9. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003, 157(11):1015-1022.
10. Nagatsu T, Sawada M Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell Mol Neurobiol 2006, 26(4-6):781-802.
11. Banerjee R, Starkov AA, Beal MF, Thomas B Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 2009, 1792(7):651-663.
12. Dawson TM, Dawson VL Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302(5646):819-822.
13. Obeso JA, Rodriguez-Oroz MC, Goetz CG, Marin C, Kordower JH, Rodriguez M, et al. Missing pieces in the Parkinson's disease puzzle. Nat Med 2010, 16(6):653-661.
14. Dawson TM, Ko HS, Dawson VL Genetic animal models of Parkinson's disease. Neuron 2010, 66(5):646-661.
15. Goedert M Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001, 2(7):492-501.
16. Lotharius J, Brundin P Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci 2002, 3(12):932-942.
17. Gasser T Molecular pathogenesis of Parkinson disease: insights from genetic studies. Expert Rev Mol Med 2009, 11:e22.
18. Lees AJ, Hardy J, Revesz T Parkinson's disease. Lancet 2009, 373(9680):2055-2066.
19. Cooper AA, Gitler AD, Cashikar A, Haynes CM, Hill KJ, Bhullar B, et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313(5785):324-328.
20. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004, 305(5688):1292-1295.
21. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, et al. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J Neurosci 2006, 26(1):41-50.
22. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001, 10(9):919-926.
23. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006, 60(5):557-569.
24. Biskup S, West AB Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochim Biophys Acta 2009, 1792(7):625-633.
25. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 2006, 52(4):587-593.
26. Sakaguchi-Nakashima A, Meir JY, Jin Y, Matsumoto K, Hisamoto N LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol 2007, 17(7):592-598.
27. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009, 12(7):826-828.
28. Tong Y, Pisani A, Martella G, Karouani M, Yamaguchi H, Pothos EN, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci USA 2009, 106(34):14622-14627.
29. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, et al. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron 2009, 64(6):807-827.
30. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392(6676):605-608.
31. Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. French Parkinson's Disease Genetics Study Group. N Engl J Med 2000, 342(21):1560-1567.
32. Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000, 25(3):302-305.
33. Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci USA 2000, 97(24):13354-13359.
34. Betarbet R, Sherer TB, Greenamyre JT Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 2005, 191(Suppl. 1):S17-27.
35. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, Costa C, et al. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005, 45(4):489-496.
36. Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003, 12(18):2277-2291.
37. Perez FA, Palmiter RD Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci USA 2005, 102(6):2174-2179.
38. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, et al. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc Natl Acad Sci USA 2004, 101(29):10744-10749.
39. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304(5674):1158-1160.
40. Silvestri L, Caputo V, Bellacchio E, Atorino L, Dallapiccola B, Valente EM, et al. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet 2005, 14(22):3477-3492.
41. Gautier CA, Kitada T, Shen J Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 2008, 105(32):11364-11369.
42. Gispert S, Ricciardi F, Kurz A, Azizov M, Hoepken HH, Becker D, et al. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009, 4(6):e5777.
43. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, Martella G, et al. From the cover: impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci USA 2007, 104(27):11441-11446.
44. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004, 279(18):18614-18622.
45. Heutink P PINK-1 and DJ-1-new genes for autosomal recessive Parkinson's disease. J Neural Transm Suppl 2006, 70:215-219.
46. Lockhart PJ, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, et al. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet 2004, 41(3):e22.
47. Tao X, Tong L Crystal structure of human DJ-1, a protein associated with early onset Parkinson's disease. J Biol Chem 2003, 278(33):31372-31379.
48. Zhang L, Shimoji M, Thomas B, Moore DJ, Yu SW, Marupudi NI, et al. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 2005, 14(14):2063-2073.
49. Cookson MR The biochemistry of Parkinson's disease. Annu Rev Biochem 2005, 74:29-52.
50. Kahle PJ, Waak J, Gasser T DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med 2009, 47(10):1354-1361.
51. Moore DJ, Dawson VL, Dawson TM Lessons from Drosophila models of DJ-1 deficiency. Sci Aging Knowledge Environ 2006, 2006:pe2.
52. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, et al. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci USA 2007, 104(37):14807-14812.
53. van der Brug MP, Blackinton J, Chandran J, Hao LY, Lal A, Mazan-Mamczarz K, et al. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc Natl Acad Sci USA 2008, 105(29):10244-10249.
54. Chen L, Cagniard B, Mathews T, Jones S, Koh HC, Ding Y, et al. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 2005, 280(22):21418-21426.
55. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005, 7(3):263-273.
56. Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006, 38(10):1184-1191.
57. Tansey MG, Goldberg MS Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2009, 37(3):510-518.
58. McGeer PL, McGeer EG Inflammation and the degenerative diseases of aging. Ann N Y Acad Sci 2004, 1035:104-116.
59. Wyss-Coray T, Mucke L Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002, 35(3):419-432.
60. Nakamura Y Regulating factors for microglial activation. Biol Pharm Bull 2002, 25(8):945-953.
61. Orr CF, Rowe DB, Halliday GM An inflammatory review of Parkinson's disease. Prog Neurobiol 2002, 68(5):325-340.
62. Ransohoff RM, Perry VH Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009, 27:119-145.
63. Tansey MG, Frank-Cannon TC, McCoy MK, Lee JK, Martinez TN, McAlpine FE, et al. Neuroinflammation in Parkinson's disease: is there sufficient evidence for mechanism-based interventional therapy?. Front Biosci 2008, 13:709-717.
64. Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, et al. A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 2009, 137(1):47-59.
65. Kurkowska-Jastrzebska I, Wronska A, Kohutnicka M, Czlonkowski A, Czlonkowska A The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 1999, 156(1):50-61.
66. Brochard V, Combadiere B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009, 119(1):182-192.
67. McGeer PL, Itagaki S, Boyes BE, McGeer EG Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38(8):1285-1291.
68. Banati RB, Daniel SE, Blunt SB Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998, 13(2):221-227.
69. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol 2003, 106(6):518-526.
70. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 1993, 52(1):1-6.
71. Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett 1995, 193(2):129-132.
72. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 1994, 180(2):147-150.
73. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995, 9(1):87-92.
74. Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J Neural Transm 1996, 103(8-9):1077-1081.
75. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996, 211(1):13-16.
76. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994, 165(1-2):208-210.
77. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994, 172(1-2):151-154.
78. Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, et al. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999, 19(9):3440-3447.
79. Stypula G, Kunert-Radek J, Stepien H, Zylinska K, Pawlikowski M Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation 1996, 3(2-3):131-134.
80. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999, 100(1):34-41.
81. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995, 202(1-2):17-20.
82. Muller T, Blum-Degen D, Przuntek H, Kuhn W Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998, 98(2):142-144.
83. Akiyama H, McGeer PL Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res 1989, 489(2):247-253.
84. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003, 18(10):2731-2742.
85. He Y, Appel S, Le W Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 2001, 909(1-2):187-193.
86. Ling Z, Gayle DA, Ma SY, Lipton JW, Tong CW, Hong JS, et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 2002, 17(1):116-124.
87. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ Synuclein activates microglia in a model of Parkinson's disease. Neurobiol Aging 2008, 29(11):1690-1701.
88. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 2008, 28(30):7687-7698.
89. Frank-Cannon TC, Tran T, Ruhn KA, Martinez TN, Hong J, Marvin M, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008, 28(43):10825-10834.
90. Lee JK, McCoy MK, Harms AS, Ruhn KA, Gold SJ, Tansey MG Regulator of G-protein signaling 10 promotes dopaminergic neuron survival via regulation of the microglial inflammatory response. J Neurosci 2008, 28(34):8517-8528.
91. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006, 21(2):404-412.
92. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005, 57(2):168-175.
93. Nishimura M, Mizuta I, Mizuta E, Yamasaki S, Ohta M, Kaji R, et al. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci Lett 2001, 311(1):1-4.
94. Wu YR, Feng IH, Lyu RK, Chang KH, Lin YY, Chan H, et al. Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet 2007, 144B(3):300-304.
95. Kruger R, Hardt C, Tschentscher F, Jackel S, Kuhn W, Muller T, et al. Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. J Neural Transm 2000, 107(5):553-562.
96. Wahner AD, Sinsheimer JS, Bronstein JM, Ritz B Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch Neurol 2007, 64(6):836-840.
97. Chen H, Jacobs E, Schwarzschild MA, McCullough ML, Calle EE, Thun MJ, et al. Nonsteroidal antiinflammatory drug use and the risk of Parkinson's disease. Ann Neurol 2005, 59:988-989.
98. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003, 60(8):1059-1064.
99. McGeer PL, McGeer EG Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis Assoc Disord 1998, 12(Suppl. 2):S1-6.
100. Samii A, Etminan M, Wiens MO, Jafari S NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs Aging 2009, 26(9):769-779.
101. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003, 100(9):5473-5478.
102. Esposito E, Di Matteo V, Benigno A, Pierucci M, Crescimanno G, Di Giovanni G Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp Neurol 2007, 205(2):295-312.
103. Barcia C, Fernandez Barreiro A, Poza M, Herrero MT Parkinson's disease and inflammatory changes. Neurotox Res 2003, 5(6):411-418.
104. Herrera AJ, Tomas-Camardiel M, Venero JL, Cano J, Machado A Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J Neural Transm 2005, 112(1):111-119.
105. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003, 991:214-228.
106. Mrak RE, Griffin WS Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging 2005, 26(3):349-354.
107. Wersinger C, Sidhu A Inflammation and Parkinson's disease. Curr Drug Targets Inflamm Allergy 2002, 1(3):221-242.
108. Zhang L, Dawson VL, Dawson TM Role of nitric oxide in Parkinson's disease. Pharmacol Ther 2006, 109(1-2):33-41.
109. Tang BL, Liou YC Novel modulators of amyloid-beta precursor protein processing. J Neurochem 2007, 100(2):314-323.
110. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X, et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003, 302(5648):1215-1217.
111. Choi DK, Pennathur S, Perier C, Tieu K, Teismann P, Wu DC, et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 2005, 25(28):6594-6600.
112. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, Agid Y, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996, 72(2):355-363.
113. Knott C, Stern G, Wilkin GP Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol Cell Neurosci 2000, 16(6):724-739.
114. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003, 100(10):6145-6150.
115. Ara J, Przedborski S, Naini AB, Jackson-Lewis V, Trifiletti RR, Horwitz J, et al. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP). Proc Natl Acad Sci USA 2009 1998, 95(13):7659-7663.
116. Przedborski S, Chen Q, Vila M, Giasson BI, Djaldatti R, Vukosavic S, et al. Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem 2001, 76(2):637-640.
117. Qureshi GA, Baig S, Bednar I, Sodersten P, Forsberg G, Siden A Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 1995, 6(12):1642-1644.
118. van der Vliet A, Eiserich JP, Halliwell B, Cross CE Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity. J Biol Chem 1997, 272(12):7617-7625.
119. Hampton MB, Kettle AJ, Winterbourn CC Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998, 92(9):3007-3017.
120. Feng Z, Li D, Fung PC, Pei Z, Ramsden DB, Ho SL COX-2-deficient mice are less prone to MPTP-neurotoxicity than wild-type mice. Neuroreport 2003, 14(15):1927-1929.
121. Sanchez-Pernaute R, Ferree A, Cooper O, Yu M, Brownell AL, Isacson O Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J Neuroinflammation 2004, 1(1):6.
122. Hunot S, Vila M, Teismann P, Davis RJ, Hirsch EC, Przedborski S, et al. JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2004, 101(2):665-670.
123. Saporito MS, Brown EM, Miller MS, Carswell S CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons in vivo. J Pharmacol Exp Ther 1999, 288(2):421-427.
124. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, Schulz JB Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 2001, 98(18):10433-10438.
125. Tansey MG, Szymkowski DE The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today 2009, 14(23-24):1082-1088.
126. Kaushal V, Schlichter LC Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 2008, 28(9):2221-2230.
127. Park KM, Bowers WJ Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 2010, 22(7):977-983.
128. Kinouchi K, Brown G, Pasternak G, Donner DB Identification and characterization of receptors for tumor necrosis factor-alpha in the brain. Biochem Biophys Res Commun 1991, 181(3):1532-1538.
129. McCoy MK, Tansey MG TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5:45.
130. Bonizzi G, Karin M The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25(6):280-288.
131. Marchetti L, Klein M, Schlett K, Pfizenmaier K, Eisel UL Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-D-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J Biol Chem 2004, 279(31):32869-32881.
132. Benasciutti E, Pages G, Kenzior O, Folk W, Blasi F, Crippa MP MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription. Blood 2004, 104(1):256-262.
133. Milne DM, Campbell LE, Campbell DG, Meek DW p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. J Biol Chem 1995, 270(10):5511-5518.
134. Noguchi K, Kitanaka C, Yamana H, Kokubu A, Mochizuki T, Kuchino Y Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J Biol Chem 1999, 274(46):32580-32587.
135. Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, Knabb JR, et al. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 2006, 13(5):712-729.
136. Tang F, Tang G, Xiang J, Dai Q, Rosner MR, Lin A The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis. Mol Cell Biol 2002, 22(24):8571-8579.
137. Butler MP, O'Connor JJ, Moynagh PN Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience 2004, 124(2):319-326.
138. Chen G, Goeddel DV TNF-R1 signaling: a beautiful pathway. Science 2002, 296(5573):1634-1635.
139. Cunningham AJ, Murray CA, O'Neill LA, Lynch MA, O'Connor JJ Interleukin-1 beta (IL-1 beta) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neurosci Lett 1996, 203(1):17-20.
140. Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, Meka DP, et al. Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J Neurosci 2008, 28(47):12500-12509.
141. McCoy MK, Martinez TN, Ruhn KA, Szymkowski DE, Smith CG, Botterman BR, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J Neurosci 2006, 26(37):9365-9375.
142. McCoy MK, Ruhn KA, Martinez TN, McAlpine FE, Blesch A, Tansey MG Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol Ther 2008, 16(9):1572-1579.
143. Wyss-Coray T Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 2006, 12(9):1005-1015.
144. Marchetti B, Abbracchio MP To be or not to be (inflamed)-is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol Sci 2005, 26(10):517-525.